Lemonaid Health

Lemonaid Health is a telemedicine platform. The company offers a treatment service for certain diseases for $25 and delivers medicines to patients from pharmacies belonging to it.

History

2021: 23andMe bought Lemonaid Health

On October 22, 2021, the 23andMe genetic testing service announced the purchase of Lemonaid Health. The transaction is expected to be completed by the end of 2021.

Under the terms of the agreement, the 23andMe will pay for Lemonaid Health for $400 million, with 25% of the purchase cost paid in cash and the rest in shares, the statement said. The deal with Lemonaid suggests that 23andMe is already on track to participate in every phase of a patient's treatment, from assessing their health risks, developing drugs to prescribing and delivering treatment, and Lemonaid Health could play another role and help find patients to participate in clinical trials of drugs developed by 23andMe.

23andMe acquired Lemonaid Health

For me, what we've always been trying to do is make the most of the human genome. Genetics has still not become part of primary care, said Chief Executive Officer Anne Wojcicki.

The first obvious point of integration with Lemonaid Health, she said, will be the use of 23andMe pharmacogenetic reports that help determine which drugs are best suited to a person when prescribed medications by Lemonaid Health physicians. Wojcicki said the company will train Lemonaid Health physicians on how to integrate genetic risk reports and pharmacogenetics into treatment. Although there is no definite roadmap for the product as of October 24, 2021, she said the ultimate goal is to create the kind of treatment that best uses genomic information. According to Anne Wojicki, the pandemic created this opportunity, since coronavirus limited the ability of patients to personally visit medical professionals and pushed crowds to switch to virtual service.

Lemonaid Health CEO and co-founder Paul Johnson, will become CEO of the consumer business 23andMe and will continue to lead this division, the statement said. Co-founder and managing director of a telemedicine company in the UK, Jan Van Every, will remain in a similar position in 23andMe.^[1]

Notes